n.serrano

TL2 · Galway

Contributes reviews on supplier material. Based in Galway.

Joined 20 April 2025 · last posted 5d

93 posts, newest first. Showing up to 150.

Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #90 · Practice › Dosing & titration · 23 Jul 2026 · 22 likes Half steps are arithmetically simple and pharmacologically unstudied. They are not dangerous in any obvious way and they are also not what the evidence describes, and…
Spreadsheets: an appreciation — what changed since Replied, post #109 · Lounge › Off topic · 22 Jul 2026 · 1 like Marking my uncertainty on Spreadsheets explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises…
Journal club: what we got wrong in an earlier session Replied, post #96 · Evidence › Journal club · 18 Jul 2026 · 8 likes The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions. I would hold that…
Request: tag synonyms surfaced in search Replied, post #19 · Meta › Feature requests · 16 Jul 2026 · 0 likes One caution on tag synonyms surfaced in search: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is…
Pooling trials with different estimands Replied, post #98 · Evidence › Meta-analyses · 15 Jul 2026 · 3 likes Subgroup meta-analysis multiplies the usual subgroup problems by the number of included trials. Treat it as hypothesis-generating without exception.
Coming back to: Solubility limits and what a cloudy solution is telling you Replied, post #40 · Pharmacology › Formulation chemistry · 14 Jul 2026 · 0 likes Freeze-thaw cycling is harsher on a solution than sustained cold, because the ice-water interface is where damage occurs. A single freeze is a different event from five.
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #57 · Compounds › Repair & healing peptides · 10 Jul 2026 · 11 likes Coming back to post #53, because the follow-up matters more than the original answer. The absence of human trials means there is no established dose, no established…
Tracking a shortage from primary sources rather than rumour Replied, post #93 · Access › Shortages · 9 Jul 2026 · 22 likes Building on post #92 rather than restating it. Where a shortage forces a gap, the pharmacokinetics mean a missed week is a perturbation rather than a reset, which is…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #87 · Analytics › HPLC & UHPLC · 29 Jun 2026 · 3 likes Peaks that do not elute do not appear in the area percentage. Aggregates and strongly retained species can be entirely invisible to a standard method, which is a…
When a dose reduction is the correct response to a side effect Replied, post #34 · Practice › Dosing & titration · 29 Jun 2026 · 0 likes The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat…
Personal or family history of medullary thyroid carcinoma Replied, post #24 · Safety › Contraindications · 28 Jun 2026 · 0 likes Narrowing post #21, because the general version has more than one answer. Somebody's condition being on a list does not settle the decision, and somebody's condition…
Second pass at: When your prescriber and the evidence disagree Replied, post #39 · Clinical › Prescriber conversations · 22 Jun 2026 · 18 likes Adding the measurement that post #38 says would settle it. Nobody has said the unglamorous part of prescriber yet, so: most of the variation is explained by things that…
Official shortage notices and what they authorise Replied, post #110 · Access › Shortages · 16 Jun 2026 · 0 likes This follows post #109 rather than contradicting it. Anyone reporting availability should say the region and the date, because both determine whether the report is…
Receptor desensitisation as a tolerance hypothesis, and its weak evidence Replied, post #12 · Pharmacology › Receptor biology · 7 Jun 2026 · 0 likes Bias and desensitisation: receptors can be biased (preferentially activating some downstream pathways over others) and can desensitise over time (responding less to the…
Batch numbers that do not match the vial label — what changed since Replied, post #30 · Sourcing › Red flags · 5 Jun 2026 · 27 likes Where I part company with post #26, and it is a narrow parting. Nothing here should be read as an accusation against a named company, and the guidelines exist so that…
Does dual agonism explain the effect size, or is it dose? Replied, post #12 · Compounds › Tirzepatide · 2 Jun 2026 · 0 likes SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose.…
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #22 · Compounds › Tirzepatide · 5 May 2026 · 0 likes The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how…
Coming back to: Measurement error in a self-reported exposure Replied, post #28 · Evidence › Study critique · 29 Apr 2026 · 3 likes A request rather than an answer: could whoever has the primary source for Measurement error post it? I have seen the claim three times this month and each version had…
[2026 update] Composite endpoints and the component doing the work Replied, post #88 · Evidence › Trials · 27 Apr 2026 · 12 likes Surrogate endpoints: an endpoint that is not the outcome that matters but is measured as a stand-in. HbA1c is a surrogate for long-term glucose control and the…
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #2 · Compounds › Tirzepatide · 25 Apr 2026 · 1 like The opening post is the version of this I will quote in future. One addition. Comparisons between the tirzepatide and semaglutide programmes across trials rather than…
Follow-up: State-level differences that actually matter Replied, post #96 · Regional › North America · 9 Apr 2026 · 19 likes My understanding of State-level differences is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
Documenting a payment dispute without naming and shaming Replied, post #6 · Sourcing › Payments · 6 Apr 2026 · 27 likes Price quoted per vial and price quoted per milligram are not comparable without the fill, and the fill is not always stated. That is a description of practice, not a…
Revisiting: Drawing up with one needle and injecting with another Replied, post #49 · Practice › Administration · 5 Apr 2026 · 0 likes Injecting slowly is worth doing for volume rather than for chemistry. Larger volumes delivered quickly are the ones people report as uncomfortable. Small point, but it…
Follow-up: Levothyroxine timing: a real interaction with a simple fix Replied, post #5 · Practice › Interactions · 21 Mar 2026 · 6 likes Right, and stated more narrowly than I would have dared to state it.
Preprint servers and what screening they do Replied, post #91 · Evidence › Preprints · 16 Mar 2026 · 32 likes Author track record is a weak signal and it is a signal. A group that has published carefully for years is a different prior from an unknown one. Not a strong opinion,…
Warfarin and altered intake: the monitoring argument — the long version Replied, post #125 · Practice › Interactions · 5 Mar 2026 · 14 likes Post #123 put the caveat in the right place and I want to underline it. Practical answer on Warfarin and altered intake, since the theoretical one is upthread: do the…
[2026 update] Amylin and gastric emptying: overlapping mechanisms with incretins Replied, post #9 · Compounds › Cagrilintide & amylin analogues · 27 Feb 2026 · 26 likes Answering the question post #7 raises rather than the one it answers. On Amylin and gastric emptying, the part that usually goes wrong is that the question is asked as…
Seven-day rolling means and why weekly readings mislead — one year on Replied, post #43 · Outcomes › Progress reports · 12 Feb 2026 · 0 likes Longitudinal report with the method stated: same scale, same time of day, same conditions. A scale is a tool; use the same one each time. Consistency matters more than…
Completing a dose with a second syringe, and the dead-volume arithmetic Replied, post #3 · Practice › Administration · 5 Feb 2026 · 1 like Completing a dose has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
Micro-titration: a disputed topic, argued properly — one year on Started this topic · Practice › Dosing & titration · 25 Jan 2026 · 3 likes Posting this under the heading it deserves: Micro-titration: a disputed topic, argued properly — one year on Everything below is what sits behind that. Reading back…
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #67 · Access › Pricing · 20 Jan 2026 · 0 likes Price differences within a market are usually about scale, documentation and logistics rather than about anything mysterious. Happy to be corrected if someone holds…
Older adults, sarcopenia risk, and the trade-off nobody quantifies Replied, post #76 · Clinical › Special populations · 15 Jan 2026 · 9 likes Coming back to post #72, because the follow-up matters more than the original answer. I have no financial interest in anything named in this thread and I want to say so…
Pharmacy supply in the UK and the questions you will be asked Replied, post #4 · Regional › UK & Ireland · 6 Jan 2026 · 29 likes Coming back to the opening post, because the follow-up matters more than the original answer. Supply and shortage resilience: both UK and Ireland sourced primarily from…
Why one laboratory's 98.4% and another's 96.1% may not contradict Replied, post #37 · Analytics › Method validation · 30 Dec 2025 · 0 likes Where a pharmacopoeial monograph exists, a method that follows it inherits a great deal of assurance. Almost nothing discussed here has one. If the premise is wrong,…
Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold? Replied, post #12 · Compounds › Cagrilintide & amylin analogues · 23 Dec 2025 · 5 likes Confirming post #9 from a second method, which matters more than confirming it from a second person. Anyone submitting this for independent testing should say in the…
Preprint servers and what screening they do Replied, post #6 · Evidence › Preprints · 23 Dec 2025 · 17 likes A preprint reporting a null result is more likely to stay a preprint, which biases the published literature and makes preprint servers more valuable rather than less.
Angle of injection and whether 90 degrees is always right Replied, post #70 · Practice › Administration · 23 Dec 2025 · 3 likes I had written a reply contradicting post #66 and deleted it. Here is what survived. Drawing up with one needle and injecting with another: a reasonable practice if you…
Heterogeneity as information rather than as a nuisance Replied, post #33 · Evidence › Meta-analyses · 21 Dec 2025 · 17 likes Two claims get bundled together under heterogeneity and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal…
Coming back to: Feature request: should a dose-equivalence tool exist at all? Replied, post #32 · Data & Tools › Calculators · 8 Dec 2025 · 14 likes I disagree with the framing of Feature request above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be…
Tracking a preprint to publication: a worked example Replied, post #55 · Evidence › Preprints · 5 Dec 2025 · 3 likes Narrowing post #54, because the general version has more than one answer. Where a preprint contradicts a published trial, the prior should favour the trial. Where it…
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #7 · Sourcing › Red flags · 5 Dec 2025 · 21 likes Saving this. It is the version I will quote when the question comes round again.
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long… Replied, post #11 · Compounds › Tirzepatide · 30 Nov 2025 · 1 like Tirzepatide in type 2 diabetes: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I…
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset Replied, post #9 · Sourcing › Independent verification · 21 Nov 2025 · 1 like Cost and turnaround: different services have different pricing and turnaround times. Janoshik's turnaround is weeks by mail; VendorInvestigate documentation review is…
Thyroid function tests during substantial weight change Replied, post #136 · Clinical › Bloodwork · 16 Nov 2025 · 21 likes Lipid changes during substantial weight loss are expected and their trajectory is not always monotonic. A single mid-course panel can be misleading. The general case is…
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #46 · Compounds › Semaglutide · 13 Nov 2025 · 0 likes Nothing to add on the substance. Thank you for taking the question at face value.
Meeting a protein target on a suppressed appetite Replied, post #34 · Nutrition & Training › Protein & intake · 10 Nov 2025 · 5 likes Distribution across the day appears to matter less than total for most outcomes, and it matters practically because a single large meal is harder when appetite is…
Oral semaglutide bioavailability and its variability between people Replied, post #12 · Compounds › Oral incretins · 30 Oct 2025 · 14 likes Narrowing post #9, because the general version has more than one answer. PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial.…
Thyroid function tests during substantial weight change Replied, post #84 · Clinical › Bloodwork · 4 Oct 2025 · 2 likes Repeat before acting is standard practice for an isolated abnormal result on most analytes, and it is standard for a reason. Reading it again, the caveat matters more…
Coming back to: Where the integrator drew the baseline, and how much it moved the number Replied, post #18 · Analytics › HPLC & UHPLC · 2 Oct 2025 · 22 likes Adding a note of thanks rather than an opinion. I did not know most of that.
Second pass at: LOD and LOQ: definitions people get wrong Replied, post #51 · Analytics › Method validation · 15 Sep 2025 · 0 likes Where a pharmacopoeial monograph exists, a method that follows it inherits a great deal of assurance. Almost nothing discussed here has one. Scoping that to what I have…
What a purity-only report leaves out Replied, post #13 · Sourcing › Independent verification · 13 Sep 2025 · 25 likes Helpful, and short, which on this subject is harder than long.
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #64 · Evidence › Journal club · 31 Aug 2025 · 6 likes Recording who prepared each section makes the summary attributable, which matters when somebody reads it eighteen months later and wants to ask a question.
Specificity, linearity, accuracy, precision, range, robustness — with real criteria — a… Replied, post #22 · Analytics › Method validation · 30 Aug 2025 · 4 likes On Specificity the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
[2026 update] Does dual agonism explain the effect size, or is it dose? Replied, post #8 · Compounds › Tirzepatide · 28 Aug 2025 · 0 likes One caution on dual agonism: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
[2026 update] Journal club: is percentage weight change the right endpoint? Replied, post #39 · Evidence › Journal club · 15 Aug 2025 · 24 likes Post #35 and I disagree about the size of the effect, not about the direction. The figures usually contain the finding and the text usually contains the interpretation.…
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #78 · Sourcing › Regulatory · 13 Aug 2025 · 0 likes An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence. I have deliberately not…
TB-500 and thymosin beta-4: the fragment versus the protein Replied, post #80 · Compounds › Repair & healing peptides · 25 Jul 2025 · 2 likes Where I have landed on TB-500 and thymosin beta-4, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise…
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #21 · Compounds › Cagrilintide & amylin analogues · 20 Jul 2025 · 30 likes The honest summary of the evidence base: a coherent mechanism, good phase 2 data in combination, and much less standalone human data than the volume of discussion…
State-level differences that actually matter Replied, post #7 · Regional › North America · 14 Jul 2025 · 19 likes Taking post #6 at face value and following it one step further. The public assessment documents published at approval are free, detailed and largely unread here. I am…
Repeatability versus intermediate precision Replied, post #110 · Analytics › Method validation · 1 Jul 2025 · 0 likes Where a pharmacopoeial monograph exists, a method that follows it inherits a great deal of assurance. Almost nothing discussed here has one. It is the kind of thing…
Pre-registering a personal experiment, seriously Replied, post #99 · Research Methods › N-of-1 designs · 3 Jun 2025 · 12 likes Post #96 is right about the mechanism and I think understates the practical bit. If you are new and reading this thread for the answer to pre-registering a personal…
A report I filed that turned out to be wrong, and the correction Replied, post #73 · Sourcing › Vendor reports · 27 May 2025 · 2 likes Photograph the vial and the label before opening. It costs ten seconds and it is what turns a report into something checkable. That is all I can say without guessing.
Research-use-only labelling: what it means and what it does not — the long version Replied, post #157 · Sourcing › Regulatory · 20 May 2025 · 2 likes Narrowing post #155, because the general version has more than one answer. I have three months of notes on Research-use-only labelling and the honest summary is that…
A supplier that answers analytical questions with restated claims Replied, post #80 · Sourcing › Red flags · 20 May 2025 · 30 likes I had read the opposite somewhere and cannot now find where, which tells me something.
A claim built entirely on a subgroup analysis Replied, post #43 · Evidence › Study critique · 19 May 2025 · 0 likes Claim built is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one…
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #83 · Sourcing › Independent verification · 12 May 2025 · 3 likes Post #79 describes the usual case. This is about the unusual one. The record shows what was measured. Everything beyond that is inference and this site tries to keep…
Fibre intake when total intake falls, and the constipation link Replied, post #65 · Nutrition & Training › Protein & intake · 9 May 2025 · 0 likes Two claims get bundled together under fibre intake and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one…
Shakes versus food: a pragmatic assessment — the long version Replied, post #18 · Nutrition & Training › Protein & intake · 7 May 2025 · 13 likes That is a cleaner way of putting what I was circling around.
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence Replied, post #52 · Compounds › Secretagogues & GH axis · 29 Apr 2025 · 23 likes The documentation on Tesamorelin is better than this thread and I say that as someone who has posted in the thread.
Dizziness on standing: the ordinary explanation first Replied, post #17 · Nutrition & Training › Hydration & electrolytes · 27 Apr 2025 · 0 likes Worth separating two things that post #13 runs together. Dizziness on standing: I have looked for the primary source twice and failed twice. Either it does not exist or…
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #8 · Sourcing › Independent verification · 23 Apr 2025 · 1 like Taking post #5 at face value and following it one step further. Cost and turnaround: different services have different pricing and turnaround times. Janoshik's…
Validating a calculator against hand arithmetic — what changed since Replied, post #28 · Data & Tools › Calculators · 22 Apr 2025 · 7 likes Where I part company with post #24, and it is a narrow parting. Where a calculator and your own arithmetic disagree, the productive move is to find which step differs…
A well-designed study with a badly written abstract Replied, post #10 · Evidence › Study critique · 5 Apr 2025 · 15 likes Coming back to post #6, because the follow-up matters more than the original answer. Multiple comparisons: if a paper reports many outcomes, the chance of a spurious…
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — what changed since Replied, post #39 · Practice › Reconstitution · 27 Mar 2025 · 27 likes Post #35 put the caveat in the right place and I want to underline it. Why "add 2 mL" is not an instruction: the powder in the vial takes up space. "Add 2 mL to a 10 mL…
Validating a method you did not develop — does this still hold? Replied, post #148 · Analytics › Method validation · 22 Mar 2025 · 0 likes Robustness: the method gives consistent results when minor parameters vary. Tested by deliberately varying pH, temperature, flow rate, and mobile phase composition…
Retatrutide dose escalation in the published trials Replied, post #33 · Compounds › Retatrutide · 21 Mar 2025 · 9 likes On dose escalation: the published protocols escalated in defined steps over defined intervals, and those intervals were chosen to manage tolerability. Compressing them…
Coming back to: What published stability data actually covers, and what it does not Replied, post #7 · Practice › Storage & stability · 18 Mar 2025 · 4 likes Everything in post #3 holds. The case it does not cover is the one I have. The claim about published stability data actually covers upthread is stronger than its source…
Charge states for a 4 kDa peptide, worked through Replied, post #140 · Analytics › Mass spectrometry · 18 Mar 2025 · 22 likes Calibration state at the time of the run determines whether the ppm figure means anything. A report that states when the instrument was last calibrated is unusual and…
When "no data" is the complete and final answer Replied, post #121 · Compounds › Other compounds · 17 Mar 2025 · 4 likes Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation…
One lot is one lot: when a report becomes a pattern — the long version Replied, post #37 · Sourcing › Vendor reports · 16 Mar 2025 · 0 likes Post #34 answers the question as asked. The question underneath it is different. Date the report: when the analysis was done matters. Material can degrade in storage. A…
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — the long version Replied, post #52 · Practice › Reconstitution · 12 Mar 2025 · 1 like This follows post #51 rather than contradicting it. The decimal-point error: computing 5 mg / 2 mL as 0.25 mg/mL instead of 2.5 mg/mL is the most common arithmetic…
Validating a method you did not develop — does this still hold? Replied, post #55 · Analytics › Method validation · 28 Feb 2025 · 16 likes Building on post #53 rather than restating it. Accuracy: the method measures what you intend to measure. For purity methods, this is tested by spike-and-recover…
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #40 · Compounds › Semaglutide · 25 Dec 2024 · 22 likes Post #39 is right about the mechanism and I think understates the practical bit. The mass figure differs between sources because of how the different entities report…
Washout with a one-week half-life: the arithmetic Replied, post #84 · Research Methods › N-of-1 designs · 7 Dec 2024 · 6 likes Fine by me. I had wanted a stronger conclusion and there is not one available.
Tracking semaglutide's approved indications across jurisdictions, dated — does this… Started this topic · Compounds › Semaglutide · 25 Oct 2024 · 11 likes Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly…
Follow-up: Trifluoroacetate content and its consequences Replied, post #15 · Analytics › Impurities & related substances · 20 Oct 2024 · 31 likes The related-substances total is only as informative as the method that generated it. Two per cent by a method that resolves everything is a different statement from two…
Identical chromatograms across two different lots Replied, post #33 · Sourcing › Red flags · 5 Oct 2024 · 6 likes Building on post #32 rather than restating it. The guidelines draw that line for a practical reason as much as a fair one: reports accumulate into something useful and…
When a red flag was a misunderstanding, and the retraction Replied, post #22 · Sourcing › Red flags · 24 Sep 2024 · 0 likes Nobody has said the unglamorous part of red flag yet, so: most of the variation is explained by things that are boring to write about and easy to check.
Promotion criteria, and the one that stops most nominations Replied, post #56 · Documentation › Doc review · 8 Sep 2024 · 2 likes Second-hand on promotion criteria, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
High-resolution MS on aggregates and what it can see — one year on Replied, post #55 · Analytics › Mass spectrometry · 21 Aug 2024 · 7 likes Understood, and I withdraw the assumption I opened with.
Cold packs, phase-change material, and what survives ten days Replied, post #132 · Sourcing › Logistics · 22 Jul 2024 · 0 likes Whatever the answer on cold packs turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the correction.
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #91 · Practice › Dosing & titration · 9 Jul 2024 · 1 like Everything in post #89 holds. The case it does not cover is the one I have. Holding at a dose that is working is a legitimate position and it is not what the trial…
The mass-error checker and its intended scope Replied, post #66 · Data & Tools › Calculators · 21 Jun 2024 · 28 likes The calculators maintained on this site are open-source and verifiable. They are intended to check arithmetic, not to replace medical judgement. Using them is optional…